FAA Research Institute Contributes to Global Study on Mepolizumab’s Effectiveness in Severe Asthma
Family Allergy & Asthma’s Dr. Stephen Pollard, Principal Investigator at the FAA Research Institute, was recently published in the Annals of Allergy, Asthma & Immunology as a co-author of a major international study: “Mepolizumab Real-World Effectiveness in Severe Asthma with an Eosinophilic Phenotype and Overlapping Severe Allergic Asthma.”
This large-scale real-world study demonstrates that mepolizumab—a biologic therapy targeting eosinophilic inflammation—significantly reduces asthma exacerbations in patients with overlapping allergic and eosinophilic phenotypes. These findings are especially relevant for clinicians managing complex asthma cases where multiple biologic options may be considered.
Research Excellence Backed by a Strong Clinical Team
This achievement would not have been possible without the outstanding efforts of our FAA Research Institute team. Becky Whitehead and Amber Noe, our dedicated research coordinators, played a vital role in patient recruitment, retention, and data management throughout the study.
While not listed as authors, their work behind the scenes was essential to the study’s success—and a testament to the quality and dedication of FAA’s clinical research staff.
Advancing Asthma Care Through Research
Participation in this peer-reviewed publication underscores Family Allergy & Asthma’s commitment to leading-edge asthma research. Our clinical research efforts help support evidence-based treatment decisions and contribute to the evolving landscape of biologic therapies for severe asthma.
